"The heart of my research is focused on ways to help improve the quality of life for people around the world. I’m passionate about developing innovative and potentially life-saving medications for patients and seeing firsthand the impact of my work."
I joined Genentech as a Scientist in October 2014 after a 9-month stint at Amgen SSF. I did my postdoctoral studies at Princeton University under the guidance of David MacMillan, where I focused on copper catalysis. Prior to my postdoctoral studies, I obtained my Doctor of Philosophy degree under the supervision of Michael Krische. My doctoral research was focused on stereoselective carbon-carbon bond forming transfer hydrogenations, utilizing ruthenium and iridium catalysis.
My education prepared me significantly for the challenges associated with drug discovery. Specifically, for solving very difficult problems correlated with developing novel chemical matter for drug targets. In my current role, I lead a chemistry team tasked with drugging a novel biological pathway.
It feels like a privilege to work at Genentech because we are so highly invested in progressing basic scientific research. Currently, I have two ongoing collaborations with Princeton University and The University of Texas. These collaborations are solely focused on pushing the limits of synthetic chemistry and developing novel bond formations. Having a postdoctoral scholar allows me to pursue these ideas at a more rapid pace. Which potentially, could have an impact on how we pursue our science on portfolio programs.
J Am Chem Soc. 2018 Jan 31;140(4):1275-1279.